Explore recent issues of Contract Pharma covering key industry trends.
Read the full digital version of our magazine online.
Stay informed! Subscribe to Contract Pharma for industry news and analysis.
Get the latest updates and breaking news from the pharmaceutical and biopharmaceutical industry.
Discover the newest partnerships and collaborations within the pharma sector.
Keep track of key executive moves and promotions in the pharma and biopharma industry.
Updates on the latest clinical trials and regulatory filings.
Stay informed with the latest financial reports and updates in the pharma industry.
Expert Q&A sessions addressing crucial topics in the pharmaceutical and biopharmaceutical world.
In-depth articles and features covering critical industry developments.
Access exclusive industry insights, interviews, and in-depth analysis.
Insights and analysis from industry experts on current pharma issues.
A one-on-one video interview between our editorial teams and industry leaders.
Listen to expert discussions and interviews in pharma and biopharma.
A detailed look at the leading US players in the global pharmaceutical and BioPharmaceutical industry.
Browse companies involved in pharmaceutical manufacturing and services.
Comprehensive company profiles featuring overviews, key statistics, services, and contact details.
A comprehensive glossary of terms used in the pharmaceutical and biopharmaceutical industry.
Watch in-depth videos featuring industry insights and developments.
Download in-depth eBooks covering various aspects of the pharma industry.
Access detailed whitepapers offering analysis on industry topics.
View and download brochures from companies in the pharmaceutical sector.
Explore content sponsored by industry leaders, providing valuable insights.
Stay updated with the latest press releases from pharma and biopharma companies.
Explore top companies showcasing innovative pharma solutions.
Meet the leaders driving innovation and collaboration.
Engage with sessions and panels on pharma’s key trends.
Hear from experts shaping the pharmaceutical industry.
Join online webinars discussing critical industry topics and trends.
A comprehensive calendar of key industry events around the globe.
Live coverage and updates from major pharma and biopharma shows.
Find advertising opportunities to reach your target audience with Contract Pharma.
Review the editorial standards and guidelines for content published on our site.
Understand how Contract Pharma handles your personal data.
View the terms and conditions for using the Contract Pharma website.
What are you searching for?
The company also made key strategic hires and signed its one hundredth commercial license agreement (CLA)
April 12, 2018
By: Betsy Louda
Selexis SA has made key strategic hires, signed its one hundredth commercial license agreement (CLA), and purchased and installed $2 million in new laboratory equipment following its acquisition by JSR Corporation in June 2017.
The new employees are to be based in Geneva, the U.S., and Tokyo, in the areas of whole genome sequencing, global business development, production and operations. The state-of-the-art laboratory equipment will be housed at the company’s laboratory facility and corporate headquarters, which opened last spring in the heart of Geneva’s biotechnology hub, and will allow Selexis to serve its growing partner base.
“Getting much-needed medicines into the hands of healthcare providers quickly and as safely as possible is – and has been – paramount to Selexis. Our commercial-ready mammalian cell line is helping partners worldwide achieve their objectives with the highest quality and predictability,” said Igor Fisch, PhD, Selexis chief executive officer. “The transition of Selexis into JSR’s Life Sciences division last year strengthened our ability to help our partners develop increasingly complex biotherapeutics such as bi-specific proteins, triabodies, DARPins and novel scaffolds decorated with peptides, to name a few. Additionally, the integration of Selexis with KBI Biopharma, a subsidiary of JSR, allows the production of drug substances for clinical trials in as little as nine months as compared to traditional industry timelines of 16 to 24 months.”
Selexis’ investment in new equipment and employees is primarily directed towards the research and development of novel and proprietary technologies that will enable Selexis to deliver high expressing and stable research cell banks (RCBs) in eight to nine weeks from transfection (currently 14 weeks).
Enter your account email.
A verification code was sent to your email, Enter the 6-digit code sent to your mail.
Didn't get the code? Check your spam folder or resend code
Set a new password for signing in and accessing your data.
Your Password has been Updated !